Home/Pipeline/177Lu-PNT6555 (w/ Novartis)

177Lu-PNT6555 (w/ Novartis)

Small Cell Lung Cancer (DLL3+)

Phase 1Active

Key Facts

Indication
Small Cell Lung Cancer (DLL3+)
Phase
Phase 1
Status
Active
Company

About PeptiDream

PeptiDream is a leader in peptide drug discovery, utilizing its innovative PDPS technology to generate diverse, non-standard peptide libraries for identifying drug candidates against 'undruggable' targets. The company has established a highly successful business model based on research collaborations and licensing agreements with global pharmaceutical giants, generating significant non-dilutive funding. Its internal and partnered pipeline spans multiple therapeutic areas, with several candidates in clinical development. PeptiDream's strategy focuses on expanding its platform's reach and advancing key proprietary assets toward commercialization.

View full company profile